

P.E.I. Pharmacare Bulletin

Issue 1 - 2018

February 14, 2018

NEW PRODUCT(S) ADDED TO THE PEI PHARMACARE FORMULARY

(Effective Date: February 26, 2018)

Product (Generic Name)	Product (Brand Name)	Strength	Dosage Form	DIN	MFR
zuclopenthixol	<u>Clopixol</u>	10mg 25mg	tab tab	02162903 02162911	LUD LUD
Criteria	open benefit				
Program Eligibility	Family Health Benefit, Financial Assistance Drug, Seniors Drug, Nursing Home Drug, Catastrophic Drug				

IMPORTANT NOTICES

Product (Generic Name)	Product (Brand Name)	Strength	Dosage Form	DIN	MFR
infliximab	<u>Remicade</u>	100mg	IV	02244016	JAN
Notice	<p>Remicade will be considered as a treatment option for infliximab naive patients as well as those patients on maintenance therapy if criteria is met for the following conditions as identified in the PEI Pharmacare Formulary (https://www.princeedwardisland.ca/sites/default/files/publications/pei_pharmacare_formulary.pdf):</p> <ul style="list-style-type: none"> • ankylosing spondylitis • crohn's disease • plaque psoriasis • psoriatic arthritis • rheumatoid arthritis <p>This coverage is effective February 15, 2018. PEI Pharmacare Formulary will identify coverage of Remicade on February 15, 2018.</p>				